Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy

Time: 3:30 pm
day: Conference Day One P3

Details:

• Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T
• Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response
• Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patients

Speakers:

Jennifer Chow Jennifer Chow is a pioneer in cell therapy, having led the launch of over 10 oncology therapeutics, including key CAR T cell therapies like Ide-cel, Read more